Tzield, approved by the FDA, in November 2022, is the first disease-modifying therapy for those at risk of developing type 1 diabetes. From funding discovery research to clinical development, to working with regulators, JDRF has had a hand in the development of Tzield from the very beginning. It all started in 1988 when JDRF awarded Dr. Kevan Herrold with a Career Development award. Dr. Herrold was the first one to prove that he could prevent autoimmune diabetes with an anti-CD3 antibody (which, later, became Tzield). He has gone on to receive more than 15 grants from JDRF and was the lead on the clinical trial that demonstrated that Tzield could delay the onset of T1D in people, like Cooper Rowen, who are certain to develop the disease.

This is a game changer. This is one step closer to cures. We invite you to watch this quick three and a half minute video of Cooper’s journey in preventing and halting his T1D diagnosis. We know we aren’t done yet and none of this would have been possible without JDRF’s support and the support of donors like you.